
hpv screening kit care gene
Benjamin
- 0
Abstract
This study assessed the clinical accuracy of the correlation between the careHPV test and the HC2 test, as well as the correlation between the careHPV test and the HPV-PCR test. From September 21 to December 31, 2009, 419 cervical specimens from women, 30–49 years, were collected. All women were assessed by Digene HC2 High-Risk HPV DNA Test (HC2), careHPV test and HPV-PCR. The concordance rate between careHPV and HC2 was 93.81% and between careHPV and HPV-PCR 88.12%. The sensitivity and specificity of the careHPV test to detect cancers of equal or greater severity than CIN 2 were 85.71% and 83.15% respectively. Results from careHPV, HC2 and HPV-PCR were highly consistent. The careHPV test has good sensitivity and specificity for the detection of HPV infection and is a promising primary screening method for cervical cancer in low-resource regions.
Introduction
Cervical cancer is the second most frequent female malignancy worldwide. High-risk human papillomavirus (HPV) is the main cause of cervical cancer, affecting nearly 500,000 women around the world every year and killing more than 270,000. About 80% of these women live in developing countries that do not have adequate cervical cancer screening or treatment programs1. Most developing countries have insufficient infrastructure for cytology-based screening and lack well-trained cytopathologists. In these countries, only a minority of women receive effective screening and treatment for cervical cancer2. Using cytology as the main method of screening is not feasible in developing countries, thus new screening methods are sought and are being evaluated, for example, visual inspection with acetic acid (VIA) and HPV-DNA testing3.

Persistent infection with HPV is the leading cause of cervical cancer and precancerous cervical lesions4. Infection with HPV is very common in young women after the onset of sexual activity. When infection persists, HPV viral oncoproteins disrupt cell-cycle controls, resulting in cervical intraepithelial neoplasia (CIN)5. Therefore, the high-risk HPV test is an effective cervical cancer screening tool. A large sample study in North America and Europe indicated that the sensitivity of the conventional Pap cytology smear for detecting cervical cancer or cancerous lesions of greater or equal seriousness to CIN 2 is only 53%. This contrasts with the Digene HC2 High-Risk HPV DNA Test (HC2) which has a sensitivity of 96.1%. The specificity of the two methods is 96.3% and 90.7%, respectively6. The Digene HC2 assay is a commercially available test for HPV DNA detection and is approved by the United States Food and Drug Administration (FDA). The HC2 assay can detect 13 types of high-risk HPV associated with cervical cancer: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. However, the HC2 assay is expensive and requires laboratory equipment, so it is not commonly available in developing countries. An international research project, supported by the Bill & Melinda Gates foundation in China and India from 2003–2007, worked towards developing a new, rapid and economical method of cervical cancer screening. One of the methods developed is a high-risk HPV nucleic acid detection kit (using hybrid capture-chemiluminescence technology) known as the careHPV test, developed by Qiagen (Gaithersburg, MD, USA)7.
The careHPV test is a powerful, rapid and precise HPV-DNA detection method in which antibodies bind to magnetic beads, rapidly capturing specific target HPV nucleic acid sequences, which are then detected using a chemiluminescence signal. This method can detect 14 types of high-risk HPV (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68) and more than 80 specimens can be processed in 2.5 hours. This allows screening and follow-up to be completed in one day.
This study assessed the clinical accuracy of the correlation between the careHPV test and the HC2 test, as well as the correlation between the careHPV test and the HPV-PCR test.
?-Amylase Inhibitor Screening Kit |
|||
K482-100 | Biovision | each | EUR 574.8 |
Lysozyme Inhibitor Screening Kit |
|||
K237-100 | Biovision | each | EUR 777.6 |
Human IgG Subclass Screening Kit |
|||
IM50 | Cygnus Technologies | 1 kit (1 ml of each antibody) | EUR 1179.6 |
Description: Human IgG Subclass Screening Kit by Cygnus Technologies is available in Europe via Gentaur. |
HDAC Inhibitor Drug Screening Kit |
|||
55R-1376 | Fitzgerald | 100 assays | EUR 990 |
Description: Screening Kit for detection of HDAC Inhibitor in the research laboratory |
PLTP Inhibitor Drug Screening Kit |
|||
55R-1448 | Fitzgerald | 100 assays | EUR 1104 |
Description: Screening Kit for detection of PLTP Inhibitor in the research laboratory |
MMP3 Inhibitor Drug Screening Kit |
|||
55R-1538 | Fitzgerald | 100 assays | EUR 1092 |
Description: Screening Kit for detection of MMP3 Inhibitor in the research laboratory |
MMP1 Inhibitor Drug Screening Kit |
|||
55R-1539 | Fitzgerald | 100 assays | EUR 1051.2 |
Description: Screening Kit for detection of MMP1 Inhibitor in the research laboratory |
HDAC3 Inhibitor Drug Screening Kit |
|||
55R-1385 | Fitzgerald | 100 assays | EUR 1051.2 |
Description: Screening Kit for detection of HDAC3 Inhibitor in the research laboratory |
HDAC8 Inhibitor Drug Screening Kit |
|||
55R-1387 | Fitzgerald | 100 assays | EUR 1051.2 |
Description: Screening Kit for detection of HDAC8 Inhibitor in the research laboratory |
PCR Quick Screening Kit, InsertFinder? |
|||
K903-500 | Biovision | each | EUR 352.8 |
KinaseSTAR JNK Activity Screening Kit |
|||
K2078-40 | ApexBio | 40 assays | EUR 769.2 |
JNK Activity Screening Kit, KinaseSTAR |
|||
K430-40 | Biovision | each | EUR 711.6 |
Human Immunoglobulin Class Screening Kit |
|||
IM40 | Cygnus Technologies | 1 kit (1 ml of each antibody) | EUR 1356 |
Description: Human Immunoglobulin Class Screening Kit by Cygnus Technologies is available in Europe via Gentaur. |
ACE1 Inhibitor Screening Kit (Colorimetric) |
|||
K719-100 | Biovision | each | EUR 1032 |
DPP4 Inhibitor Screening Kit (Fluorometric) |
|||
K780-100 | Biovision | each | EUR 744 |
pCAF Inhibitor Screening Kit (Fluorometric) |
|||
K345-100 | Biovision | each | EUR 686.4 |